Online inquiry

IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2605MR)

This product GTTS-WQ2605MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ICOSLG gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001283050.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 23308
UniProt ID O75144
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2605MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10731MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA M-281
GTTS-WQ15781MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ11599MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ15387MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA TRU-016
GTTS-WQ12037MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ12534MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ1936MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ2807MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG-301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW